Yuki Noguchi
Stories
-
The new obesity drugs work, but it's a dilemma when people have to stop taking them
-
National
How dairy production is changing in response to avian flu
New measures to stop avian flu among dairy cows are taking effect, such as testing dairy herds before they cross state lines. But farmers who voluntarily report infections stand to lose money.
-
Biden administration abandons plan to ban menthol cigarettes, citing 'feedback'
An anti-smoking advocate says the decision to leave menthol cigarettes on the market "prioritizes politics over lives, especially Black lives."
-
National
Americans are sleeping less. This podcaster wants to help change that
More than half of Americans say they'd benefit from more sleep. A woman has made it her business to help people get better sleep via a podcasting company that focuses on meditation.
-
After 40 years of smoking, she survived lung cancer thanks to new treatments
Scientific advances in immunotherapy and new targeted therapies have increased survival rates. But screening among former and current smokers still needs to improve to save more lives.
-
Medicare plans can now cover Wegovy for patients at risk of heart disease
This change follows the recent FDA approval of the weight-loss drug for preventing heart attack and stroke in people with overweight or obesity.
-
The fight over banning menthol cigarettes has a long history steeped in race
Black smokers make up menthol tobacco's largest market, and have the highest rates of lung cancer. But the fight over banning menthol is a complex and divisive issue in the Black community.
-
Another Ozempic side effect? Facing the holidays with no appetite
Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.
-
Lung cancer survival rates rise, but low screening rates leave many people at risk
A new survey finds more people are surviving lung cancer and racial disparities are shrinking. But unless it's caught early, lung cancer still has a low survival rate.
-
FDA approves Zepbound, a new obesity drug that will take on Wegovy
Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.